Skip to main content

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston.

TD Cowen 45th Annual Health Care Conference, March 3-5, 2025
Event details:
Date: Monday, March 3, 2025
Time: 2:30 pm ET
Location: Boston, MA

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

Chris Calabrese 
LifeSci Advisors 
ccalabrese@lifesciadvisors.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.14
+4.77 (2.32%)
AAPL  251.49
+3.50 (1.41%)
AMD  202.68
+1.35 (0.67%)
BAC  47.52
+0.36 (0.76%)
GOOG  299.02
+0.23 (0.08%)
META  604.06
+10.40 (1.75%)
MSFT  383.00
+1.13 (0.30%)
NVDA  175.64
+2.94 (1.70%)
ORCL  154.34
+4.66 (3.11%)
TSLA  380.85
+12.89 (3.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.